SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Cox G, Vyberg M, Melgaard B, Askaa J, Oster A, O'Byrne KJ. Herceptest: HER2 expression and gene amplification in non small cell lung cancer. Int J Cancer. 2001; 92: 480483.
  • 2
    Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20: 719726.
  • 3
    Love RR, Duc NB, Havighurst TC, et al. HER-2/neu over-expression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor positive premenopausal women with operable breast cancer. J Clin Oncol. 2003; 21: 453457.
  • 4
    Berry DA, Muss HB, Thor AD, et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol. 2000; 18: 34713479.
  • 5
    Burstein JH, Harris LN, Marcum PK, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter Phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors and cardiac surveillance algorithm. J Clin Oncol. 2003; 2: 28892895.
  • 6
    Kern JA, Schwartz DA, Nordberg JE, et al. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 1990; 50: 51845187.
  • 7
    Kern JA, Torney L, Weiner D, et al. Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody. Am J Respir Cell Mol Biol. 1993; 9: 448454.
  • 8
    Dacic S, Ramalingam S, Luketich J, et al. Fluorescent in situ hybridization (FISH) evaluation of HER-2/neu and cyclin D1 expression in non-small cell lung cancer (NSCLC): correlation with clinical behavior [abstract 2622]. Proc Am Soc Clin Oncol. 2003; 22: 652.
  • 9
    Therasse P. Measuring the clinical response. What does it mean? Eur J Cancer. 2002; 38: 18171823.
  • 10
    Warr D, McKinney S, Tannock I. Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response. J Clin Oncol. 1984; 2: 10401046.
  • 11
    Gatzemeier U, Groth G, Hirsh V, et al. Gemcitabine/cisplatin alone and with trastuzumab (Herceptin) in patients with non small cell lung cancer over-expressing HER2: results of a randomized Phase II study [abstract 1185]. Proc Am Soc Clin Oncol. 2002; 21: 297a.
  • 12
    Tran JT, Herbst RS, Glisson BS, et al. Herceptin in combination with cisplatin and gemcitabine in patients with HER2 over-expressing, untreated, advanced, non small cell lung cancer: final report of a Phase II trial [abstract 1226]. Proc Am Soc Clin Oncol. 2002; 21: 307a.
  • 13
    Gatzemeier U, Groth G, Butts C, et al. Randomized Phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non small cell lung cancer. Ann Oncol. 2004; 15: 1927.
  • 14
    Levitzki A. EGF receptor as a therapeutic target. Lung Cancer. 2003; 41: S9S14.
  • 15
    Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non small cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 21292139.
  • 16
    Gianni L. Tolerability in patients receiving trastuzumab with or without chemotherapy. Ann Oncol. 2001; 12(Suppl 1): S63S68.
  • 17
    Radzikowska E, Szczepulska E, Chabowski M, Bestry I. Organizing pneumonia caused by trastuzumab (Herceptin) therapy for breast cancer. Eur Respir J. 2003; 21: 552555.